Repotrectinib

Buy Repotrectinib (Augtyro) capsules online in India
Generic Name/API:Repotrectinib
Storage:Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F)
Dosage:For dosage information, please visit the General Information section.
Strength:Capsules of 40 mg and 160 mg
Indication:Repotrectinib is an oral prescription cancer medicine used to treat ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors. It is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases.

Repotrectinib is a kinase inhibitor indicated for the treatment of 

  • adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).  • adult and pediatric patients 12 years of age and older with solid tumors that :
    • have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and 
    • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity. 
    • have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials

Repotrectinib is an oral prescription cancer medicine used to treat ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors. It is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases.

Strength: 

Capsules of 40 mg and 160 mg

Dosage: 

The recommended dosage of Repotrectinib for adult and pediatric patients 12 years of age and older is 160 mg taken orally once daily with or without food for 14 days, then increase to 160 mg twice daily and continue until disease progression or unacceptable toxicity.

Adverse Reactions: 

The most common adverse reactions (≥20%) were dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, and nausea.

Storage:

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F)

  • Central Nervous System (CNS) Effects: Can cause CNS adverse reactions including dizziness, ataxia, and cognitive impairment. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue AUGTYRO based on severity. 
  •  Interstitial Lung Disease (ILD)/Pneumonitis: Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Immediately withhold in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed. 
  •  Hepatotoxicity: Monitor liver function tests every 2 weeks during the first month of treatment, and as clinically indicated thereafter. Based on severity, withhold and then resume at same or reduced dose, or permanently discontinue. 
  • Myalgia with Creatine Phosphokinase (CPK) Elevation: Monitor serum CPK levels during treatment in patients reporting unexplained muscle pain, tenderness, or weakness. Based on severity, withhold and resume at same or reduced dose upon improvement. 
  • Hyperuricemia: Monitor serum uric acid levels prior to initiating and periodically during treatment. Initiate treatment with urate-lowering medications as clinically indicated. Withhold and resume at same or reduced dose, or permanently discontinue based on severity. 
  • Skeletal Fractures: Promptly evaluate patients with signs or symptoms (e.g., pain, changes in mobility, deformity) of fractures. 
  •  Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use an effective non-hormonal method of contraception.

Process to Import Medicine

FAQ

Repotrectinib (Augtyro) inhibits abnormal ROS1 and TRK fusion proteins, blocking downstream signaling pathways that promote tumor growth and survival. This results in inhibition of cancer cell proliferation and induction of apoptosis.

Repotrectinib (Augtyro) is administered orally as capsules, with or without food, as directed by a healthcare professional.

If a dose is missed, it should generally be skipped if the next scheduled dose is due soon. Patients should not take two doses at the same time to make up for a missed dose and should follow the product labeling or their healthcare provider’s instructions.

Repotrectinib treatment is generally continued until disease progression or unacceptable toxicity occurs, as determined by the treating healthcare professional.

The price of repotrectinib (Augtyro) in India may vary, as the medicine is not approved in India and must be imported. Pricing depends on product availability, import-related costs, and applicable regulatory requirements. For the latest pricing details and availability, please contact 24/7 QualityMeds at +919967979080.

To buy Augtyro (repotrectinib) capsules online in India, a valid prescription and applicable regulatory documentation are required. 24/7 QualityMeds assists with prescription verification, import documentation, and the lawful procurement of the medicine in accordance with Indian regulations.

To buy repotrectinib (Augtyro) capsules in Delhi, a valid prescription is required. 24/7 QualityMeds assists with checking medicine availability, prescription verification, and delivery in accordance with applicable regulatory requirements.

Related products